Assays and screens; other

TECHNOLOGY: Cell-free assays; computational models

A computational model based on mutations in plasma cell-free DNA (cfDNA) could help predict the time to progression in mCRC patients treated with anti-EGFR therapies.

Read the full 297 word article

How to gain access

Continue reading with a
two-week free trial.